05/06/2020

Merck's Biosimilar ONTRUZANT® (trastuzumab-dttb) is Available through Specialty Distributors and Wholesalers

Merck Sharp & Dohme Corp. (“Merck”), a subsidiary of Merck & Co., Inc., is pleased to announce that ONTRUZANT^® (trastuzumab-dttb) for injection, for intravenous use 21 mg/mL, a biosimilar^* to Herceptin^® (trastuzumab), is available through specialty distributors and wholesalers. Please contact your specialty distributor or wholesaler to confirm product availability.

*Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of ONTRUZANT has been demonstrated for the condition(s) of use (eg, indication(s), dosing regimen(s), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information).

ONTRUZANT is available as follows:

Indications and Usage: CLICK HERE

Selected Safety Information: CLICK HERE